Investigational drug · Phase 3
Pirarubicin Hydrochloride
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NMIBC.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
46
Any phase or sponsor naming "Pirarubicin Hydrochloride"
First trial start
2026
Jul 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pirarubicin Hydrochloride", any sponsor or status.
- Phase 228
Conditions studied
As listed on its trial records.
- NMIBC
Largest trials
Live from ClinicalTrials.gov: studies naming "Pirarubicin Hydrochloride" as an intervention, largest first.
- Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruiting
Chinese Academy of Medical SciencesAcademic, hospital or other
NCT05287308 · 500 participants (planned) · Start Mar 2022 · Primary completion Sep 2027
Drug: doxorubicin; epirubicin and 5 more · For: Breast Cancer
Sites: Beijing, China
- Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1Pivotal-lookingCompleted
Eastern Hepatobiliary Surgery HospitalAcademic, hospital or other
NCT02724358 · 320 participants · Start Dec 2012 · Primary completion Dec 2013
Drug: Rg3 · For: Hepatocellular Carcinoma; TACE; Notch1 and 1 more
Sites: Shanghai, China
- DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast CancerPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT02838225 · 300 participants · Start Jan 2009 · Primary completion Jan 2016
Drug: Docetaxel, Doxorubicin; Docetaxel, Doxorubicin, Cyclophosphamide · For: Breast Cancer
- Breast Cancer Treatment Based on Organ-like CultureStatus unknown
Xijing HospitalAcademic, hospital or other
NCT03925233 · 300 participants (planned) · Start Jan 2, 2019 · Primary completion Dec 15, 2021
Drug: Trastuzumab; Doxorubicin Hydrochloride and 27 more · For: Breast Cancer Organoids
Sites: Xi'an, China
- Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast CancerPivotal-lookingStatus unknown
Hebei Medical University Fourth HospitalAcademic, hospital or other
NCT02903524 · 300 participants (planned) · Start Sep 2016 · Primary completion Sep 2018
Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide; pirarubicin and cyclophosphamide · For: Breast Cancer
Sites: Shijiazhuang, China
- Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyPivotal-lookingRecruiting
Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04437160 · 286 participants (planned) · Start Feb 1, 2020 · Primary completion Jan 2026
Drug: Epirubicin or Pirarubicin; Cyclophosphamide · For: Triple Negative Breast Cancer
Sites: Beijing, China
- Combine TACE and RFA Versus TACE Alone for HCC With PVTTPivotal-lookingStatus unknown
Ming ZhaoAcademic, hospital or other
NCT02301091 · 240 participants (planned) · Start Oct 2014 · Primary completion Oct 2018
Drug: pirarubicin,mitomycin and lobaplatin · For: Hepatocellular Carcinoma
Sites: Guangzhou, China
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07424287 · 236 participants (planned) · Start Jul 13, 2026 · Primary completion Jun 2030
Drug: SHR-1501 for Injection; BCG for Injection and 5 more · For: NMIBC
Sites: Beijing, China; Shanghai, China
- DEB-TACE+HAIC vs. HAIC for Large HCCPivotal-lookingStatus unknown
Second Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT05263219 · 230 participants (planned) · Start Feb 10, 2022 · Primary completion Feb 9, 2026
Drug: dTACE-HAIC protocol; HAIC protocol · For: Unresectable Hepatocellular Carcinoma
Sites: Guangzhou, China
- Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial CarcinomaPivotal-lookingStatus unknown
RenJi HospitalAcademic, hospital or other
NCT03030157 · 220 participants (planned) · Start Jan 2017 · Primary completion Jan 2020
Drug: pirarubicin(THP) · For: Intravesical Instillation
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization.
Song PW, Liu YH, Wang T, et al. · World J Surg Oncol 2023
- Anaphylactic shock due to intravesical administration of pirarubicin hydrochloride for the fifth time.
Sakata K, Fukuoka N, Tanabe K, et al. · J Clin Anesth 2016
- The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Wang HF, Lv JQ · Cell Biochem Biophys 2015
- Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma.
Wang N, Lv YZ, Xu AH, et al. · Asian Pac J Cancer Prev 2014
- [Perforation in the primary T-cell lymphoma of the small intestine due to effective chemotherapy-a case report].
Ebihara T, Nakata K, Fukunaga M, et al. · Gan To Kagaku Ryoho 2013
- [Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
Su J, Li MQ, Xu H, et al. · Zhonghua Yi Xue Za Zhi 2011
Also in development for NMIBC
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- SHR-1501Phase 34 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Papillary-Only Non-muscle-invasive Bladder Cancer, Patients With Advanced or Metastatic Malignant Tumors, NMIBC
- SPGL008Phase 22 trials
Shenyang Sunshine Pharmaceutical Co., LTD. · NMIBC, Non Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.